Guardant Health (GH) stock
NASDAQ
As of the Nov 13, 2026 close (U.S. Eastern)
Events and reference metrics · 1
- Market cap
- $20.5B
- As of Nov 13, 2026
- P/E
- -42.31x
- Trailing twelve months
- P/B
- Not available
- Latest reported equity
- P/S
- 16.00x
- Trailing twelve months
- ROE
- Not available
- Trailing twelve months
- Dividend yield
- Not available
- Latest fiscal-year dividends
Multiples use the price as of Nov 13, 2026 and may differ from the current price.
- Market cap
- $20.5B
- As of Nov 13, 2026
- P/E
- -42.31x
- Trailing twelve months
- P/B
- Not available
- Latest reported equity
- P/S
- 16.00x
- Trailing twelve months
- ROE
- Not available
- Trailing twelve months
- Dividend yield
- Not available
- Latest fiscal-year dividends
Multiples use the price as of Nov 13, 2026 and may differ from the current price.
Compares the share price with the company's earnings, net assets and sales. Check trading status and financial notes separately.
Price date for the multiples · Nov 13, 2026 · Financial period · Trailing twelve months
P/E and P/S use the latest four quarters where available · P/B uses the latest equity · Computed in-house by ChickenStock
P/E
-42.31x
Net loss — not comparable
P/B
—
P/S
16.00x
Earnings and dividend metrics▾
Earnings
EPS
-$3.59
Earnings per share
BPS
—
Book value per share
ROE
—
Return on equity
- EPS — what one share earned over the last four quarters. The company is currently loss-making, at $3.59 per share.
ⓘ What are these valuation metrics?▾
P/E = share price ÷ earnings per share (EPS)
P/B = share price ÷ book value per share (BPS)
P/S = share price ÷ sales per share
P/E shows how many times annual earnings per share the price is; not all earnings are paid to shareholders. P/B compares the price with net assets, and P/S with sales.
Higher or lower is not good or bad by itself. Typical levels differ by industry; read P/B alongside ROE and P/S alongside margins.
ChickenStock computes these from SEC financial filings: net income and revenue are summed over the latest four quarters, and equity is the latest reported balance.
A negative P/E means a net loss. Reference information only, not a recommendation to buy or sell.
Latest earnings
SEC filingsJul–Sep 2026(FY2026 Q3)
Revenue increased 36.2% from the same period a year earlier.
Key reported figures come first. Select one to see the same quarter across three years.
Revenue · same quarter, three years
Year-ago quarter $265M+36.2%
$191M
Jul–Sep '24
$265M
Jul–Sep '25
$361M
Jul–Sep '26
The next earnings date has not been confirmed yet.
ⓘ Notes on these figures▾
- Results for Jul–Sep 2026 are from the 10-Q submitted to SEC EDGAR on Nov 5, 2026.
- Earnings per share decreased from a year earlier. The year-ago value was zero or negative, so no percentage change is shown.
- Revenue increased 36.2% from the same quarter a year earlier.
- Operating income decreased from a year earlier. The year-ago value was zero or negative, so no percentage change is shown.
- Net income decreased from a year earlier. The year-ago value was zero or negative, so no percentage change is shown.
Filed Nov 5, 2026 · 10-Q · SEC EDGAR
Reported results are from SEC EDGAR filings. Reference information only, not investment advice.
Insider transactions
Recent Form 4 filings grouped by person, date and transaction type.
- Azar Alex M IIDirector · Nov 12, 2026Option exercise138 shares · $0Avg. price $01,031 shares held after
- MIGNONE ROBERTODirector · Oct 21, 2026Option exercise264 shares · $0Avg. price $010,538 shares held after
- Hidalgo Medina ManuelDirector · Oct 17, 2026Option exercise232 shares · $0Avg. price $05,252 shares held after
- Tariq MusaDirector · Oct 16, 2026Open-market sale116 shares · $19KAvg. price $165.8811,583 shares held after
- Tariq MusaDirector · Oct 15, 2026Option exercise250 shares · $0Avg. price $011,699 shares held after
- Azar Alex M IIDirector · Oct 14, 2026Open-market sale69 shares · $11KAvg. price $159.89893 shares held after
- Azar Alex M IIDirector · Oct 12, 2026Option exercise137 shares · $0Avg. price $0962 shares held after
- Eltoukhy HelmyCo-Chief Executive Officer · Oct 1, 2026Shares withheld for taxes17,087 shares · $3.0MAvg. price $174.751,958,949 shares held after
- Talasaz AmirAliCo-Chief Executive Officer · Oct 1, 2026Shares withheld for taxes17,087 shares · $3.0MAvg. price $174.751,842,366 shares held after
- Chudova DaryaChief Technology Officer · Oct 1, 2026Shares withheld for taxes4,320 shares · $755KAvg. price $174.7574,348 shares held after
- Bell Michael BrianChief Financial Officer · Oct 1, 2026Shares withheld for taxes3,914 shares · $684KAvg. price $174.7555,182 shares held after
- Saia John G.Chief Legal Officer · Oct 1, 2026Shares withheld for taxes3,706 shares · $648KAvg. price $174.7542,348 shares held after
- Freeman ChrisChief Commercial Officer · Oct 1, 2026Shares withheld for taxes3,143 shares · $549KAvg. price $174.7569,647 shares held after
- Kalia KumudChief Information Officer · Oct 1, 2026Shares withheld for taxes3,067 shares · $536KAvg. price $174.7542,773 shares held after
- Monroe Terilyn J.Chief People Officer · Oct 1, 2026Shares withheld for taxes2,098 shares · $367KAvg. price $174.7524,900 shares held after
- Chudova DaryaChief Technology Officer · Oct 1, 2026Option exercise8,033 shares · $0Avg. price $0
Show 4 price lots
- 1,701 shares × $0$0
- 3,324 shares × $0$0
- 1,668 shares × $0$0
- 1,340 shares × $0$0
- Talasaz AmirAliCo-Chief Executive Officer · Oct 1, 2026Option exercise33,713 shares · $0Avg. price $0
Show 2 price lots
- 23,997 shares × $0$0
- 9,716 shares × $0$0
- Monroe Terilyn J.Chief People Officer · Oct 1, 2026Option exercise4,019 shares · $0Avg. price $0
Show 2 price lots
- 2,659 shares × $0$0
- 1,360 shares × $0$0
- Freeman ChrisChief Commercial Officer · Oct 1, 2026Option exercise7,416 shares · $0Avg. price $0
Show 4 price lots
- 1,929 shares × $0$0
- 1,668 shares × $0$0
- 2,527 shares × $0$0
- 1,292 shares × $0$0
- Kalia KumudChief Information Officer · Oct 1, 2026Option exercise6,046 shares · $0Avg. price $0
Show 4 price lots
- 1,607 shares × $0$0
- 1,084 shares × $0$0
- 1,995 shares × $0$0
- 1,360 shares × $0$0
- Eltoukhy HelmyCo-Chief Executive Officer · Oct 1, 2026Option exercise33,713 shares · $0Avg. price $0
Show 2 price lots
- 23,997 shares × $0$0
- 9,716 shares × $0$0
- Saia John G.Chief Legal Officer · Oct 1, 2026Option exercise7,063 shares · $0Avg. price $0
Show 4 price lots
- 974 shares × $0$0
- 1,668 shares × $0$0
- 2,925 shares × $0$0
- 1,496 shares × $0$0
- Bell Michael BrianChief Financial Officer · Oct 1, 2026Option exercise7,280 shares · $0Avg. price $0
Show 3 price lots
- 2,085 shares × $0$0
- 3,324 shares × $0$0
- 1,871 shares × $0$0
Only transactions reported on SEC Form 4 are shown. A sale may follow a pre-arranged 10b5-1 plan, and items such as option exercises or shares withheld for taxes are not open-market trades.
Recent SEC filings
40 filingsFilings submitted to the U.S. Securities and Exchange Commission (EDGAR). Dates are SEC filing dates (U.S. Eastern). Form and item names are the official SEC titles. The Earnings and Risk tags come directly from form types and item codes; they are not written by AI. Insider ownership reports (Forms 3, 4 and 5) are excluded.
Company overview
Expand ▾
Guardant Health (GH) stock information
NASDAQ
Guardant Health (GH) is listed on NASDAQ. Its market capitalization is about $20.5B. On trailing-twelve-month earnings the P/E ratio is -42.31. These figures are computed in-house from official filings and are reference information only.
Guardant Health — frequently asked questions
- What is the P/E ratio of Guardant Health (GH)?
- On a trailing-twelve-month basis, GH trades at a P/E ratio of -42.31. It is calculated as market capitalization divided by net income attributable to controlling interests, using official filings. Reference information only.
- What is the market capitalization of Guardant Health?
- GH has a market capitalization of about $20.5B. The figure moves with the share price and is refreshed each trading day.
- Is this page investment advice?
- No. Every figure on this page is factual reference information compiled from public filings. It is not investment advice, not a price forecast and not a recommendation to buy or sell. Investment decisions rest with the user.
All metrics, scores, and content provided by ChickenStock are reference information derived from market data. They are not investment advice or a solicitation to trade. Investment decisions and their consequences rest with the user.